M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Repligen Corp to acquire Avitide Inc.
Announced Sep 16, 2021 · Closed Sep 20, 2021 · Private target
Deal value$150M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationNot disclosed
Transaction
- Acquirer
- Repligen Corp (RGEN)
- Target
- Avitide Inc.
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Sep 20, 2021
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Perella Weinberg
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)